---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-083664"
form_type: "8-K"
ticker: "CVRX"
cik: "0001235912"
company_name: "CVRx, Inc."
filed_at: "2022-07-28T23:59:59+00:00"
generated_at: "2026-06-24T07:19:05.472570+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CVRx Q2 revenue $5.0M (+61% YoY); HF revenue up 90% in US; FY guidance raised

## Summary
- Revenue $5.0M (+61% YoY), US HF revenue $3.8M (+90% YoY) driven by territory expansion.
- Active US implanting centers reached 71 (+27% QoQ); sales territories grew to 20 from 8 a year ago.
- Net loss narrowed to $11.1M ($0.54/shr) from $17.7M; cash $121.3M at quarter end.
- FY2022 revenue guidance raised lower end to $20.5M (range $20.5-$23.0M); gross margin guidance 75-76%.
- Received FDA approval for new tablet programmer and MR conditional labeling for Barostim.

## SEC filing metadata
- accession: 0001104659-22-083664
- form_type: 8-K
- ticker: CVRX
- cik: 0001235912
- company_name: CVRx, Inc.
- filed_at: 2022-07-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1235912/000110465922083664/0001104659-22-083664-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1235912/000110465922083664/tm2221895d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-083664
- JSON: https://secwatch.observer/filing/0001104659-22-083664.json
- Plain text: https://secwatch.observer/filing/0001104659-22-083664.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.